Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy

Trial Profile

Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs MK 2206 (Primary) ; Selumetinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 28 May 2015 Results will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Array BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top